Hengrui PD-1 monoclonal antibody has once again submitted an application for listing in the USA. Will it replicate the approval path of Keytruda monoclonal antibody? | Speed Reading Announcement
①Today, jiangsu hengrui pharmaceuticals announced that it will resubmit the application for approval of Carirelizumab in the USA, after previously receiving a Complete Response Letter (CRL) from the US FDA, causing a delay; ②Junshi Bio's PD-1 variety also experienced delays in the USA but eventually succeeded in getting approved, industry insiders suggest that hengrui may replicate this process; ③If successfully approved in the USA, it would be of great significance to hengrui pharmaceuticals' global strategy.
Controlling shareholder's high quality pledge rate questioned, Tonghua Dongbao: revenue will gradually recover in the second half of the year | Earnings conference direct hit
①The high pledge rate of tonghua dongbao pharmaceutical's controlling shareholder's shares has been questioned, company's chairman Li Jiahong stated that it was due to the long investment cycle of Dongbao Group's projects; ② In terms of performance, Li Jiahong predicts that the company's revenue will gradually recover in the second half of the year; ③ The company also introduced the sales situation of new products.
Bullish on A-shares? Foreign capital bypasses Hong Kong stock ETFs, with institutions suggesting that incremental capital for Chinese stocks may reach 40 billion US dollars.
Institutions predict that Chinese stock potential incremental funds may reach 40 billion US dollars. Which directions will be the focus of increasing positions?
What happened during the National Day holiday at home and abroad? Here is a summary of important financial news.
①The Shanghai Stock Exchange: Will extend the acceptance of designated trading order instructions starting from October 8; Goldman Sachs has raised the Chinese stock market to "overweight", expecting a further increase of 15-20%; ②The Hong Kong stock market is booming, with a high growth in the number of brokerage account openings and margin trading data in Hong Kong in the past week; Many places have introduced optimization policies for real estate, and the market has responded positively.
Hong Kong stocks become the "hottest" stock market in the world! The Hang Seng Index has risen nearly 40% so far this year, with brokerage stocks surging sixfold in five days. How will the future market evolve?
It is noteworthy that brokerage stocks, as the vanguards of the bull market, play the role of "front-runners" in this current uptrend. Moreover, Chinese-affiliated brokerage stocks in the Hong Kong market have shown astonishing increases, indicated by the gains over the past five trading days.
Express News | Contract research organizations surged violently in the final trading session of Hong Kong stocks, with Tigermed soaring nearly 28%, Pharmaron rising over 22%, Joinn Laboratories up more than 17%, Wuxi Apptec up over 16%, and Wuxi Bio up over 14%.
Hong Kong stocks have been soaring for days on heavy volume, haven't jumped on board yet? These directions are still worth paying attention to.
In recent days, the heavy-duty policy bullish continues to catalyze, with large funds actively buying assets in China, and the market's bullish sentiment towards China has been fully ignited. Beneficiary sectors have already risen in advance. Lowering mortgage rates is bullish for consumer spending, with sectors like alcohol, gold, and jewelry taking the lead, while opportunities for biomedical and real estate stocks are worth looking forward to.
Another wave! The revised version of the 'Biosecurity Bill' in the U.S. Senate has been included in the legislative schedule, but the suspense of 'crossing the pass' still remains.
①On the 23rd local time in the United States, the U.S. Senate included Amendment S.3558 in the Senate legislative agenda by general order, and determined the new name of the bill, with unusual movements in the pharmaceutical industry. ② Amendment S.3558 did not incorporate the "grandfather clause" regarding exemptions period from the U.S. House version of the Biosecurity Act, nor made any changes to the entities involved.
Humanwell healthcare's "autumn of many events": Controlling shareholder is being applied for reorganization, previously penalized by regulators | Speed Reading Notice
1. Tonight, humanwell healthcare announced that its controlling shareholder Contemporary Technology has applied for restructuring, which has been accepted, there is a possibility of a change in control of humanwell healthcare; 2. Humanwell healthcare, its controlling shareholder Contemporary Technology, and the actual controller have been repeatedly monitored and sanctioned by regulatory authorities; 3. Earlier this year, executives of humanwell healthcare have successively reduced their shareholding, and the 2024H1 performance continues the trend of 'increased revenue but not increased profit' from 2023.
"Miracle drug" for reducing fever – An Gong Niu Huang Wan and Zhangzhou Pientzehuang Pharmaceutical are being recalled in many places, causing a decline in market prices | Industry News
①The price of Angong Niuhuang Pills and Zinc Ingot of Zhangzhou Pientzehuang Pharmaceuticals has dropped, with a decrease of more than 100 yuan per pill/ingot. ②With the production and marketization of cultivated musk in the body, as well as the pilot project of lifting the ban on the import of natural musk in China, industry insiders expect that the tight supply and demand situation of musk raw materials will be alleviated.
Massive layoffs? Remegen responds: it is a normal business optimization. The new indications for Tai Itasi will be submitted for listing in the near future.
①Regarding the rumor of layoffs circulating on the internet, the secretary of the board of directors of remegen stated that the company started to streamline its business from last year, and the optimization of positions and personnel is based on work needs without a rigid ratio; ②The other party revealed that the severe myasthenia gravis indication of the targeted drug tazepamab will be applied for market approval in the near future. However, in the market, tazepamab is facing multiple competitions.
Intends to acquire medical instruments dealer micro-tech for 0.29 billion, accelerating its overseas expansion.
①CME is a channel company for the sale of medical equipment products located in Europe, with sales advantages in products such as endoscopy. ②In recent years, to offset the domestic impact, micro-tech's overseas income has gradually increased, reaching 0.624 billion yuan in the first half of 2024, accounting for 46.78% of the overall income.
Listed companies have carried out a intensive buyback this week! Wuxi apptec has launched its third "cancellation-style" buyback plan of the year, with a maximum buyback amount of 0.1 billion yuan A-share. Here is a list of the names.
①This week, the A-share listed companies continue to buy back stocks. According to incomplete statistics from Caixin, 11 listed companies plan to repurchase up to 0.1 billion yuan (see table); ②wuxi apptec, following the completion of the first two repurchase plans on February 5 and May 22, announced another 1 billion yuan repurchase plan on Tuesday evening. After the repurchase is completed, all repurchased shares will be cancelled and the registered capital will be reduced.
Top oncology conference is coming! Multiple popular anti-cancer drugs will debut, involving these A-share companies.
①The annual meeting of the European Society for Medical Oncology will be held in Barcelona, Spain in 2024; ②At the meeting, Beigene, Jiangsu Hengrui Pharmaceuticals and other listed companies will release the latest data on their oncology drugs; ③In addition, the conference will also discuss cutting-edge topics such as the impact of artificial intelligence on the diagnosis and treatment of tumors.
Quick Look at Mid-day Trading | The three major stock indexes in Hong Kong all fell, with oil and coal stocks declining; all three major oil companies saw a drop of over 5%, while Tianqi Lithium Corporation surged 12% against the market trend.
Network technology stocks generally fell, with SenseTime down nearly 3%, JD.com, Netease down nearly 1%, Tencent, Alibaba slightly down; Bilibili rose by over 1%, Meituan slightly rose.
Another unreasonable suppression! The U.S. House of Representatives has passed the Biosecurity Act, and wuxi apptec and wuxi bio have quickly responded.
①The U.S. House of Representatives passed the draft of the Biosecurity Act (H.R.8333) with 306 votes in favor and 81 votes against. ②Wuxi Apptec, Wuxi Bio, and other companies strongly opposed it. ③This bill still needs to be voted on by the Senate and the versions passed by both houses need to be reconciled before it can be submitted to the U.S. President for signing into law.
"There are already a certain number of orders"! Can the nano-pore sequencer with a selling price of 0.4 million become a "booster" for Huada's performance?
On the 9th, BGI Group released two new nanopore sequencers, WT02 and WY01. WT02 is available for order now, and WY01 is planned to be launched in the first half of 2025. In the first half of 2024, both BGI Manufacturing and BGI Genomics experienced pressure, with high expectations on the two new nanopore sequencers from BGI Manufacturing. Chief Operating Officer of BGI Manufacturing, Jiang Hui, stated that a certain number of orders have already been generated.
BGI has launched a nanopore gene sequencing machine. Wang Jian: China needs to take a leading role in the development of life sciences.
① With the release of the nanopore gene sequencing instrument, Huada Group has become the only global institution that masters ultra-high throughput, ultra-low cost, and ultra-long read length sequencers. ② Wang Jian, the chairman of Huada Group, stated that China should take a leading role in the future development of life sciences and the bioeconomy based on big data, paving the way for global development and support.
A subsidiary has been "blacklisted" by Shenzhen for one year. Jointown Pharmaceutical Group claims to be "in the process of defending". The industry believes that the intensity of procurement supervision is continuously increasing.
Recently, Jointown Pharmaceutical Group's subsidiary, Jointown Medical Device, was fined and banned from participating in Shenzhen procurement for one year due to providing false information in a tender at a hospital in Shenzhen. Jointown Pharmaceutical Group responded to a reporter from Caijing.com.cn, stating that this incident is a pending matter, and they have organized appeal materials and are currently undergoing administrative reconsideration. This year, several listed companies have been fined for violations in the bidding and procurement process, leading industry insiders to suggest that companies should pay more attention to compliance with details during the bidding process.
Is the GLP-1 pipeline progressing slowly? Gan & Lee Pharmaceuticals: GZR18 has the potential for superior weight reduction efficacy compared to multi-target drugs | Live coverage of the earnings conference.
At the earnings conference, the management of Gan & Lee Pharmaceuticals emphasized that the price regression of the company's insulin products in the follow-up volume procurement has driven the performance. In the face of doubts about the progress of GLP-1 pipeline research and competitiveness, Dou Kai, the General Manager of Gan & Lee Pharmaceuticals, stated that GZR18 injection has a weight loss effect that exceeds exenatide and dulaglutide, and has the potential to be superior to multi-target GLP-1RA drugs in weight loss efficacy.